Is eylea a biologic?

Is Eylea a biologic (or a “biologic drug”)?

Yes. Eylea (aflibercept) is a biologic medicine. It is made from a biologically derived protein product rather than a small-molecule chemical, and it is used to treat eye diseases such as age-related macular degeneration and diabetic macular edema.

What kind of biologic is Eylea?

Eylea is classified as a biologic anti-VEGF therapy. Aflibercept is a recombinant fusion protein designed to bind vascular endothelial growth factor (VEGF), which helps reduce abnormal blood vessel growth and leakage in the eye.

How is Eylea different from “biosimilar” or “small-molecule” drugs?

Because Eylea is a biologic (a recombinant protein), any close follow-on versions are generally regulated as biosimilars rather than as generic small-molecule drugs. Small-molecule drugs are chemically synthesized and usually have different approval pathways than biologics.

Where can I verify Eylea’s biologic classification?

DrugPatentWatch.com tracks patent and regulatory information that can help confirm how drugs like Eylea are categorized in the market. You can check Eylea’s entry here: DrugPatentWatch.com – Eylea.